1. Targeting lung cancer cells with MUC1 aptamer-functionalized PLA-PEG nanocarriers.
- Author
-
Shahrad S, Rajabi M, Javadi H, Karimi Zarchi AA, and Darvishi MH
- Subjects
- Apoptosis, Cell Line, Tumor, Doxorubicin therapeutic use, Drug Carriers chemistry, Drug Delivery Systems methods, Humans, Mucin-1, Polyesters chemistry, Polyethylene Glycols chemistry, Lung Neoplasms drug therapy, Nanoparticles chemistry
- Abstract
MUC1 aptamer-functionalized PLA-PEG nanocarriers at various w/w ratios (polymer to doxorubicin weight ratio) were prepared by a double emulsion method. Physiochemical properties, encapsulation efficiency (EE), loading content (LC) and in vitro release kinetics of DOX were assessed. Furthermore, cytotoxicity and antitumor activity of prepared PLA-PEG-Apt/DOX NPs at w/w ratio 10:1 were evaluated by MTT assay and flow cytometry against MUC1-overexpressing A-549 cell line. Targeted nanocarriers (PLA-PEG-Apt/DOX NPs at w/w ratio 10:1) induced higher apoptosis rate (36.3 ± 3.44%) for 24 h in MUC1 positive A-549 cancer cells in compare to non-targeted form (PLA-PEG/DOX NPs at w/w ratio 10:1, 11.37 ± 1.65%) and free DOX (4.35 ± 0.81%). In other word, the percentage of cell death in A-549 lung cancer cells treated with PLA-PEG-Apt/DOX NPs at w/w ratio 10:1 is 3.19 and 8.34 fold higher than in non-targeted form and Free DOX treated cancer cells, respectively. Therefore, PLA-PEG-Apt/DOX NPs might be considered a promising drug delivery system for targeted drug delivery towards MUC1-overexpressing tumors cells., (© 2022. The Author(s).)
- Published
- 2022
- Full Text
- View/download PDF